- Sun Pharma's Baska facility in Gujarat classified as OAI by USFDA after inspection
- Inspection took place from September 8 to September 19, 2025
- OAI status may delay approval of pending product applications from the facility
Sun Pharmaceutical Industries Ltd. on Thursday said the US health regulator has classified its Baska facility in Gujarat under Official Action Indicated (OAI) category following an inspection.
The US Food and Drug Administration (USFDA) conducted the inspection at the plant from September 8 to September 19, 2025.
The USFDA has subsequently determined that the inspection classification status of this facility is OAI the Mumbai-based drug major said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
As per the USFDA, OAI implies that the regulator may withhold approval of any pending product applications or supplements filed from such facility till the outstanding observations related to non-compliance of manufacturing norms laid down by it.
“We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,” the drug maker said.
Shares of the company were trading 2.38% down at Rs 1,752.40 apiece on BSE.
ACME Solar Secures Rs 4,725 Crore Financing For Renewable ProjectsEssential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
